Cohen Yuval
SEC CIK 1626003 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | CEO, Dir | 157.3K | $6,795 | $3.76M | 14 | 2022-03-09 | 2026-08-07 |
Most active insiders at CRBP, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Cohen Yuval | CEO, Dir | — | $750.5K |
| 2 | Moran Sean F. | CFO | — | $378.5K |
| 3 | Chen Bihua | 10% | — | $344.1K |
| 4 | Saxena Nishant C | Chief Business Off | $126.3K | — |
| 5 | Smethurst Dominic | Chief Medical Off | — | $77.2K |
| 6 | Altmeyer Anne | Dir | — | $40.8K |
| 7 | Jenkins John Kenneth | Dir | — | $38.0K |
| 8 | Hodgson Ian | COO | — | $25.8K |
| 9 | Kung Winston | Dir | — | $16.0K |
| 10 | Ben Yong | Dir | — | $15.7K |
Transactions 14
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-08-10 16:30 | 2026-08-07 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Cohen Yuval | CEO, Dir | S - Sale | $10.08 | -17.0K | 157.3K | -10% | -$171.4K |
| T | 2026-02-18 | 2026-02-13 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Cohen Yuval | CEO, Dir | S - Sale | $7.78 | -13.9K | 174.3K | -7% | -$107.9K |
| D | 2026-01-16 | 2026-01-14 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Cohen Yuval | CEO, Dir | A - Grant | $0.00 | +50.0K | 188.2K | +36% | $0 |
| DMT | 2025-10-27 | 2025-10-24+ | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Cohen Yuval | CEO, Dir | S - Sale+OE | $17.05 | -27.6K | 138.2K | -17% | -$471.2K |
| DMT | 2025-10-27 | 2025-10-24+ | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Cohen Yuval | CEO, Dir | M - OptEx | $4.26 | +27.6K | 147.2K | +23% | +$117.7K |
| T | 2025-02-18 | 2025-02-14 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Cohen Yuval | CEO, Dir | S - Sale | $8.76 | -7,134 | 138.2K | -5% | -$62.5K |
| D | 2025-02-04 | 2025-01-31 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Cohen Yuval | CEO, Dir | A - Grant | $0.00 | +68.1K | 145.3K | +88% | $0 |
| DMT | 2024-06-18 | 2024-06-14+ | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Cohen Yuval | CEO, Dir | M - OptEx | $17.14 | +56.2K | 86.2K | +187% | +$962.9K |
| DMT | 2024-06-18 | 2024-06-14+ | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Cohen Yuval | CEO, Dir | S - Sale+OE | $46.57 | -63.4K | 77.2K | -45% | -$2.95M |
| D | 2024-02-14 | 2024-02-12 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Cohen Yuval | CEO, Dir | A - Grant | $0.00 | +73.9K | 84.4K | +707% | $0 |
| D | 2024-01-30 | 2024-01-26 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Cohen Yuval | CEO, Dir | M - OptEx | $4.97 | +7,179 | 7,179 | New | +$35.7K |
| 2022-08-11 | 2022-08-10 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Cohen Yuval | CEO, Dir | P - Purchase | $0.26 | +3,800 | 98.2K | +4% | +$988 | |
| 2022-05-16 | 2022-05-16 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Cohen Yuval | CEO, Dir | P - Purchase | $0.25 | +10.5K | 94.4K | +13% | +$2,625 | |
| 2022-03-09 | 2022-03-09 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Cohen Yuval | CEO, Dir | P - Purchase | $0.37 | +8,600 | 83.9K | +11% | +$3,182 |
Purchase Sale Sale after option exercise All abbreviations